Association between baseline vitamin D metabolite levels and long-term cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial:protocol for a cohort study with patient-record evaluated outcomes by Herly, M et al.
Syddansk Universitet
Association between baseline vitamin D metabolite levels and long-term
cardiovascular events in patients with rheumatoid arthritis from the CIMESTRA trial
Herly, Mette ; Stengaard-Pedersen, K.; Hørslev-Petersen, Kim; Hetland, M L; Østergaard, M;
Christensen, R; Løgstrup, Brian B; Vestergaard, P; Pødenphant, J.; Junker, Peter; Ellingsen,
Torkell Juulsgaard
Published in:
BMJ open
DOI:
10.1136/bmjopen-2016-014816
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC
Citation for pulished version (APA):
Herly, M., Stengaard-Pedersen, K., Hørslev-Petersen, K., Hetland, M. L., Østergaard, M., Christensen, R., ...
Ellingsen, T. (2017). Association between baseline vitamin D metabolite levels and long-term cardiovascular
events in patients with rheumatoid arthritis from the CIMESTRA trial: protocol for a cohort study with patient-
record evaluated outcomes. BMJ open, 7(4), [e014816]. DOI: 10.1136/bmjopen-2016-014816
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 13. aug.. 2017
Association between baseline vitamin D
metabolite levels and long-term
cardiovascular events in patients with
rheumatoid arthritis from the
CIMESTRA trial: protocol for a cohort
study with patient-record evaluated
outcomes
M Herly,1,2 K Stengaard-Pedersen,3 K Hørslev-Petersen,4 M L Hetland,5
M Østergaard,5 R Christensen,6 B B Løgstrup,7 P Vestergaard,8 J Pødenphant,9
P Junker,1 T Ellingsen1
To cite: Herly M, Stengaard-
Pedersen K, Hørslev-
Petersen K, et al. Association
between baseline vitamin D
metabolite levels and long-
term cardiovascular events in
patients with rheumatoid
arthritis from the CIMESTRA
trial: protocol for a cohort
study with patient-record
evaluated outcomes. BMJ
Open 2017;7:e014816.
doi:10.1136/bmjopen-2016-
014816
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-014816).
Received 21 October 2016
Revised 3 March 2017
Accepted 6 March 2017
For numbered affiliations see
end of article.
Correspondence to
Mette Herly;
Mette.herly@rsyd.dk
ABSTRACT
Introduction: Cardiovascular morbidity and mortality
is increased in patients with rheumatoid arthritis (RA),
and among these patients, the prevalence of
hypovitaminosis D is high. Moreover, low vitamin D
levels have been associated with increased
cardiovascular risk in healthy subjects.
Objective: To evaluate the long-term risk of
cardiovascular events in patients having low total
25-hydroxyvitamin D levels at baseline compared with
patients with normal levels, in an efficiently treated,
closed cohort of patients with an early diagnosis of
RA.
Methods and analysis: This study is a prospective,
closed, blinded endpoint cohort study, based on
secondary analyses from a previous randomised trial
(CIMESTRA study; NCT00209859, approved
September 1999) including 160 patients with an early
diagnosis of RA from Danish University clinics.
Primary outcome will be the proportion of patients with
any cardiovascular event in the follow-up period,
evaluated using systematic journal audits. Logistic
regression models will test the hypothesis that there
are more cardiovascular events in enrolled patients
with a low level of vitamin D (< 50 nmol/L).
Secondarily, Cox regression models, based on survival
analysis, will determine the extent to which
independent variables (including different levels of
vitamin D at baseline) predict whether a cardiovascular
event will occur, and also when this will be.
Ethics and dissemination: All patients have received
verbal and written information before enrolment, and
have given written consent at baseline. To disseminate
comprehension of factors of prognostic importance to
cardiovascular outcome in RA, we will attempt to have
a first draft ready no later than 1 year after the
adjudication process has finished. If low vitamin D
levels can predict cardiovascular events in RA, it is
relevant to take into account in a prediction model, to
be considered by patients, physicians and other
decision-makers.
Trial registration number: The parental controlled
trial is registered as NCT00209859.
INTRODUCTION
Cardiovascular disease is a major burden in
rheumatoid arthritis (RA); the risk of
cardiovascular events in patients with RA has
been estimated to be the same size as the
risk in patients with type II diabetes.1 2
Furthermore, patients with RA develop car-
diovascular events 5–10 year earlier than
Strengths and limitations of this study
▪ The long follow-up period in this early,
treated-to-target rheumatoid arthritis (RA) cohort
allows long-term prospective evaluation of car-
diovascular events in patients with RA.
▪ Data are acquired by patient-record evaluation
according to a predefined algorithm.
▪ The use of a previous controlled trial with strict
exclusion criteria excludes patients with
comorbidities at baseline and might weaken the
external validity.
▪ Patients are allocated according to baseline
vitamin D, which may be associated with other
baseline characteristics, thereby confounding the
results.
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non-RA patients,3 and the mortality in patients with RA
who have their ﬁrst cardiovascular event is higher than
in matched non-RA patients.4 Mortality in RA is decreas-
ing,5 but apparently not at the same pace as in the back-
ground population, and the mortality gap is still present,
mostly associated with comorbid conditions in patients
with RA.6 The question is, why is the mortality in RA still
increased, and why do patients with RA die earlier than
the general population?
Vitamin D, well-known for its calcium-homoeostatic
properties, is also a potent immune modulator; with
vitamin D receptor and vitamin D metabolising enzymes
being present in all types of immune cells.7 By inhibiting
the innate immune system and modulating the adaptive
immune system, the prevalence of autoimmune disease
might be affected by low vitamin D levels.8 Vitamin D
insufﬁciency is common in patients with RA,9 and may be
even more prevalent than in the general population.10–12
Some epidemiological studies have shown signiﬁcant
associations between low vitamin D and the prevalence of
autoimmune disease, including RA,13 whereas recent
studies and meta-analyses question this association.14 15
Also, myocytes and cells of the vessel walls contain
vitamin D receptor and enzymes essential for vitamin D
metabolism, and low levels of vitamin D are associated
with several cardiovascular risk factors.16 In non-RA sub-
jects, epidemiological studies consistently show signiﬁ-
cant associations between low vitamin D levels and
increased cardiovascular disease.17–21 Atherosclerosis has
become accepted as an inﬂammatory state,22–24 and the
main proinﬂammatory cytokines involved in the athero-
sclerotic process, such as interleukin 1, interleukin 6
and tumour necrosis factor α,25–27 are also pivotal in
RA.28 29 Interestingly, in vitro studies show that the
immune cells responsible for the production of these
proinﬂammatory cytokines are upregulated when
matured in a milieu low in vitamin D.30 This concomi-
tance might reveal a potential promising role of vitamin
D in the risk of cardiovascular disease in patients with
RA, further underlined by the ﬁnding that classic cardio-
vascular risk factors are commonly shared in patients
with RA and patients with vitamin D insufﬁciency.31
However, the role of vitamin D in the evolvement of
cardiovascular disease in RA, and in non-RA subjects, is
controversial, owing to the close relationship between
vitamin D and several factors known to increase the risk
of cardiovascular disease, such as body composition,
lipid metabolism and lifestyle factors such as smoking
and sedentary lifestyle. These are considered below.
Patients with RA are often obese or have an altered
body composition.32 33 In those with a low or normal
body mass index (BMI), rheumatoid cachexia (low
muscle mass, high fat mass) may be present,34 35 leading
to an altered distribution of body fat and muscle mass;
obesity and altered body composition are also obvious
cardiovascular risk factors. Vitamin D sequesters in fatty
tissue, and high fat mass, can thereby lead to lower
levels of circulating bioavailable vitamin D.36
Low levels of vitamin D are associated with a sedentary
lifestyle,37 often due to lack of sun exposure and thereby
cutaneous vitamin D production during ultraviolet B
radiation. Patients with RA, especially those with active
disease and high disability, often have a sedentary,
indoor lifestyle, thereby increasing the probability of
having lower vitamin D levels.
Smoking is a well-known risk factor for the develop-
ment of atherosclerosis,38 one of the main-steps in the
development of cardiovascular disease. Smoking can
also be a part of the pathogenesis in RA, where it leads
to early citrullination, and thereby, production of auto-
antibodies.39 40 In non-RA subjects, smoking is asso-
ciated with lower levels of vitamin D than found in
matched non-smokers.41–43
Patients with RA often have the ‘lipid paradox’—that
is, low levels of total cholesterol, low-density lipoprotein
(LDL) and high-density lipoprotein, but a remaining
high risk of cardiovascular disease (CVD).44 45 Likewise,
in patients with RA, an inverse association has been
observed between vitamin D levels and LDL,46 indicating
that vitamin D might be associated with known cardio-
vascular risk factors in patients with RA.47–49
Other comorbidities in RA, such as insulin resist-
ance,50 hypertension51 and metabolic syndrome,52 are
highly prevalent, and similarly, low levels of vitamin D
are linked to these comorbidities,53 which are all known
to be individual risk factors of CVD.
An eventual aetiological role of low vitamin D levels in
the development of CVD is important, as it is potentially
remediable. Most interventional studies of the effect of
vitamin D treatment on autoimmunity, CVD and overall
mortality are not convincing.54–60 On the other hand,
low vitamin D levels might still be able to predict excess
mortality,61 and thereby guide the clinician′s attention
towards the need for prevention in patients at risk of
increased morbidity and mortality.
The objective of this study is, in patients with an early
diagnosis of RA who are treated-to-target since diagnosis,
to evaluate the association between low vitamin Dtotal
levels at baseline (deﬁned as Dtotal < 50 nmol/L) and
occurrence of cardiovascular events during long-term
follow-up, to test the prespeciﬁed hypothesis that low
vitamin D levels at baseline predict an increased risk of
cardiovascular events during follow-up.
METHODS
Study design
This prospective cohort study is based on the Danish
CIMESTRA trial.62 The study design was initially a 2-year
randomised controlled trial and thereafter followed in
an open design for 14–17 years with a continuous
treat-to-target strategy, aiming at remission63 for the
whole period.
All data were prospectively registered: RA disease activ-
ity parameters in the DANBIO registry and the cardio-
vascular events in the patients’ records. The current
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study allocates the patients in two groups, according
to baseline Dtotal levels. This protocol conforms to
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) statement64 because the
study, with allocation of the patients in two groups
according to baseline Dtotal levels and subsequent
follow-up, will report the probability of having a cardio-
vascular event in the group with low levels of Dtotal, com-
pared with the group with normal levels. The
subsequent reporting of the cohort study will conform
to the ‘STrengthening the Reporting of OBservational
studies in Epidemiology’ (STROBE) statement.65 The
risk of bias is assessed using the ROBINS-I guidelines.66
Participants
One hundred and sixty treatment-naive patients with an
early diagnosis of RA were originally recruited from ﬁve
Danish University clinics (trial centres) from October
1999 to completion October 2002. Mean age at inclu-
sion was 53 years (range 20.4–75.2). Further baseline
characteristics are described elsewhere.62 Inclusion cri-
teria: fulﬁlling American College of Rheumatology 1987
criteria for RA,67 disease duration < 6 months, two or
more swollen joints and age between 18 and 75 years.
Exclusion criteria: glucocorticoid treatment 4 weeks
before inclusion, previous use of disease-modifying
antirheumatic drugs, malignancy, diastolic blood pres-
sure > 90 mm Hg, elevated serum creatinine, infections
with parvovirus B19, hepatitis B, C and HIV, and any
condition contraindicating the study medication. The
ﬁrst 2 years of the CIMESTRA trial consisted of two
treatment arms: (1) methotrexate (MTX) + ciclosporin
A (CsA) (initial combination therapy group) and (2)
MTX + placebo-CsA (initial monotherapy group).
Intra-articular corticosteroids for suppression of joint
synovitis were allowed in both arms of the trial from
week 76 to week 104; CsA/placebo-CsA were tapered to
zero while MTX was continued. From week 68, hydroxy-
chloroquine 200 mg per day was added to both arms.
Oral prednisolone was not allowed during the ﬁrst
2 years. From year 3 to 5, intra-articular glucocorticoid
injections and MTX 20 mg per week were continued. If
activity persisted, the patients were switched to triple
therapy (MTX, sulfasalazine and hydroxychloroquine)
and the next possible step-up was MTX + tumor necrosis
factor α inhibitor. For further details, see the original
article.62 At 5 years, 50% of the patients were treated
with MTX or MTX and hydroxychloroquine, 16%
received triple therapy, while 17% were receiving bio-
logical treatment. Seventeen per cent had withdrawn
from the treatment because of ≥12 months’ American
College of Rheumatology remission.68 Before ﬁnal ana-
lysis of this study, treatment at year 10 will also be
known.
All patients were recommended daily supplementation
with folic acid 1 mg per week and daily oral intake of
vitamin D3 (400 IU/10 mg) and calcium (500 mg). As
part of the Danish National Recommendations for
osteoporosis prophylactic all patients with RA were
reminded of the supplementation when seen by the
physician during follow-up visits.
Exposure and control group
Baseline vitamin Dtotal will be dichotomised at 50 nmol/L,
based on the international cut-off value.69 The group with
vitamin Dtotal < 50 nmol/L will be evaluated as primary
‘exposure’ and the group of patients with vitamin Dtotal ≥
50 nmol/L will be evaluated as having a normal level of
vitamin D.
Outcomes and variables
Cardiovascular events, deﬁned as hospitalisation or
death due to acute or elective cardiovascular diseases,
are diagnosed by the patients’ medical records. Likewise,
non-cardiovascular reasons for hospitalisations and
deaths will be evaluated for future use. The use of
patients records in evaluating cardiovascular events were
validated by Gaede et al.70–72 The working group
members (MH and TE) will not be blinded to the
patients’ baseline vitamin D status. We assume that non-
blinding of the two evaluators to the patients’ medical
records is unlikely to affect the adjudication of the
objective outcome ‘any cardiovascular event’.
The follow-up time will be calculated in months from
date of entry (from October 1999—October 2002) and
to time of ﬁrst cardiovascular event, to death owing to
cardiovascular or non-cardiovascular reasons, to with-
drawal of informed consent or to 10 October 2016,
whichever comes ﬁrst. The result of the classiﬁcation will
be entered in REDCap (project-redcap.org), provided
by OPEN (Odense Patient data Explorative Network) via
an encrypted connection, fulﬁlling the demands for
data security by logging all data entries and changes.
Evaluation of the primary outcome: any cardiovascular
event
The primary outcome is the occurrence of a ﬁrst hos-
pitalisation due to myocardial ischemia, heart failure,
apoplexia cerebri, arrhythmia, procedure-related
cardiovascular event, other cardiovascular reasons and
supposed cardiovascular reasons, or death from cardio-
vascular reasons. Patients experiencing any of these con-
ditions will be deﬁned as ‘having a cardiovascular event’,
and thereby experiencing the primary outcome. See
ﬁgure 1.
Adjudication of events
Hospitalisation will be subclassiﬁed as follows:
1. Hospitalisation due to acute reasons
2. Hospitalisation due to elective reasons
An acute hospitalisation is deﬁned as an unscheduled
hospitalisation, and is further deﬁned as a minimum
one overnight stay at the hospital. The hospitalisation
will be dated as the date when admitted to the ﬁrst over-
night stay in the hospital.
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Acute hospitalisation will be deﬁned as non-
cardiovascular or cardiovascular, based on the total hos-
pitalisation, and will further be subclassiﬁed as follows:
Non-cardiovascular hospitalisation
Non-cardiovascular hospitalisation will be subdivided
into cancer, infection, respiratory disease, trauma,
suicide and other causes of non-cardiovascular
hospitalisation.
Cardiovascular hospitalisation
1. Myocardial ischemia:
A. Non-fatal or fatal myocardial infarction,
deﬁned by national and international
guidelines.73
B. Fatal myocardial infarction is deﬁned as a
primary fatal event within 7 days, documented
by post mortem autopsy, or by the deﬁnition of
myocardial infarction according to European
guidelines.73
C. Death of myocardial infarction as a conse-
quence of medical examination/procedure/
surgery will be classiﬁed as procedure-related
death.
D. Acute coronary syndrome includes acute
ischaemic symptoms with eventual elevation of
biomarkers or electrocardiographic changes
which does not fulﬁl the criteria of acute myo-
cardial infarction.
E. Angina pectoris.
F. Revascularisation procedures (percutaneous
coronary intervention or coronary artery bypass
graft).
2. Heart failure:
A. Patients with non-elective hospitalisation or
death, minimum one overnight stay, with symp-
toms or ﬁndings of heart failure.
B. Death due to heart failure is deﬁned as escalat-
ing heart failure symptoms before death.
3. Arrhythmias:
A. Atrial ﬁbrillation or ﬂutter, supraventricular
tachycardia and others.
B. Ventricular tachycardia, ventricular ﬁbrillation
and others.
C. Death due to arrhythmia requires documenta-
tion—for example, telemetric transcript, pace-
maker output or electrocardiogram.
4. Stroke:
A. Cerebral haemorrhage, cerebral thromboembol-
ism, transitory cerebral ischaemia and others.
B. Stroke is deﬁned as abrupt severe neurological
deﬁcits, eventually with CT documentation.
Figure 1 Classification of events in the CIMESTRA cohort.
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Death within 14 days after symptom-onset of
stroke, and without other obvious reasons, is
classiﬁed as caused by stroke.
C. Death from stroke as a consequence of medical
examination/procedure/surgery, and without
other obviously reasons, is classiﬁed as caused
by stroke.
5. Procedure-related event:
A. Any cardiovascular event within 24 hours after
cardiovascular medical examination/proced-
ure/surgery.
6. Other cardiovascular hospitalisations:
A. Hospitalisation caused by other cardiovascular
events —for example, pulmonary embolism,
rupture of aortic aneurism, etc.
7. Supposed cardiovascular hospitalisation:
A. Hospitalisations without any documented non-
cardiovascular cause.
B. All deaths which are not deﬁned by the cardio-
vascular reasons mentioned above, and which
are not caused by well-documented non-
cardiovascular death.
C. All deaths without known reason.
Elective hospitalisation will be classiﬁed as either non-
cardiovascular (subclassiﬁed as cancer, infection, respira-
tory diseases, trauma, suicide and other for future use)
or cardiovascular, which is further subclassiﬁed as
follows:
1. Myocardial ischemia
2. Arrhythmia
3. Heart failure
4. Others.
The cause of death will be deﬁned as cardiovascular, if a
non-cardiovascular cause of death is not identiﬁed.
Cardiovascular death will be further classiﬁed by time, as
either sudden or non-sudden death. Sudden cardiovas-
cular death is described as either witnessed, if death is
witnessed and abrupt within 1 hour after symptom-onset,
or non-witnessed with no obvious non-cardiovascular
reasons (found dead) The remaining cardiovascular
deaths will be classiﬁed as non-sudden.
Endpoints and time
All endpoints will be classiﬁed according to the deﬁni-
tions mentioned above. Therefore the patients might
have more than one event, and even during one single
hospitalisation, the patient might have more than one
event, but for the primary analyses they will only count
as ‘having an event’, classiﬁed as either cardiovascular or
non-cardiovascular.
Other measurements
Baseline disease activity was evaluated by the Disease
Activity Score calculated with C reactive protein on 28
joints. Disability status was self-reported according to the
Danish validated version of the Stanford Health
Assessment Questionnaire.74 Patient-estimated global
health was assessed on a Visual Analogue Scale 0–100
mm.75 The number of swollen joints and number of
tender joints were evaluated by the treating rheumatolo-
gist. Systolic and diastolic blood pressure were obtained
on the right arm with the patient in a sitting position
after 5 min rest, using the mean value of two repetitive
measurements with 1–2 min between them.
Baseline body weight and height were measured, and
BMI calculated as BMI=weight/height squared (kg/m2)
was categorised as normal (BMI ≤ 25), overweight (BMI
>25 < 30) and obese (BMI ≥ 30). Blood samples at base-
line are evaluated for 25OHD2, 25OHD3, 1,25(OH)2D,
C reactive protein (CRP), anti-citrullinated peptide anti-
bodies (ACPA) and IgM rheumatoid factor (IgM RF).
ACPA and IgM RF are dichotomised as positive versus
negative, according to national reference values.62
Patients were asked about smoking at baseline, and
smoking status will be dichotomised as ever or never.
Vitamin D metabolite measurements
Serum ascertained at baseline, before initiation of treat-
ment and before calcium and vitamin D supplementa-
tion, was stored at −80°C. Storage time was up to
15 years. After being thawed, 25OHD2 and 25OHD3
were analysed in serum by isotope dilution liquid chro-
matography–mass spectrometry (LC-MS/MS) using cali-
brators traceable to international standard reference
material NIST SRM 972.76 Mean coefﬁcients of variation
for 25OHD3 were 8.1% at 48 nmol/L and 9.6% at
25 nmol/L, and for 25OHD2, the coefﬁcients of vari-
ation were 8.5% at 23 nmol/L and 8.0% at 64 nmol/L.
Vitamin Dtotal was calculated as the sum of 25OHD2 and
25OHD3, and dichotomised at 50 nmol/L.
Baseline routine laboratory measurements
IgM RF was detected by ELISA.77 ACPA IgG antibodies
were determined by a second-generation ELISA
(Immunoscan RA kit, Euro-diagnostica AB, Malmo,
Sweden) with the recommended 25 U/mL cut-off point.78
Serum CRP was measured using standard laboratory
measures.
The distribution of baseline variables in the two vitamin
D groups will be presented in table form (table 1).
Eventual differences in the distribution of baseline
variables in the two vitamin D groups will be discussed
to evaluate potential confounders of the association
between Dtotal level and cardiovascular mortality.
Data collection, management and confidentiality
The baseline data are electronically stored in clinical
databases approved by Danish Health Authorities. The
patient consent form is stored in paper form and has
been kept locked at the individual inclusion sites. The
outcome adjudication will start when chief consultants at
the participating clinics approve access to the patient′s
journals. The data entry will be performed using the
REDCap browser (project-redcap.org) using password-
protected areas, thereby logging any admission as well as
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alterations by using personal log-in and password for any
of the adjudicators.
For future use, the dataset concerning the cardiovascu-
lar outcome will be stored inﬁnitely at the Danish Data
Archive (https://www.sa.dk/en/services/danish-data-archive).
Statistical methods
Sample size and power considerations
The sample size (n=160) was predeﬁned from the exist-
ing CIMESTRA study.62 From the CARMA study it is
known that the prevalence of low vitamin D in patients
with RA is approximately 40%.9 This is in agreement
with other studies of vitamin D levels in patients with
incident RA, as well as in patients with established
RA.11 15 79–81 We ﬁnd the assumption of a 40% preva-
lence of low vitamin D levels in our cohort reasonable.
Originally, our study protocol aimed to evaluate cardio-
vascular death as the primary outcome, but we learnt
that there were only 11 deaths in the cohort during
the ﬁrst 10 years of follow-up. Therefore, we agreed to
use ‘any cardiovascular event’ as primary outcome,82 to
enable the study to have sufﬁcient statistical power. The
authors and the working group have no knowledge
about cardiovascular events in the study before the
journal adjudication. Moreover, to achieve a substantially
greater power, by probably implicating more events, we
have extended the follow-up period from the originally
planned 10 years after inclusion (October 2009—
October 2012) to the 10th of October 2016, thereby fol-
lowing up the patients for up to 17 years. In a recent
meta-analysis in 41 490 patients, the pooled hazard ratio
for any incident cardiovascular event in patients with RA
was 1.48, compared with non-RA-patients.83 For non-RA
patients, two meta-analyses of cardiovascular disease in
relation to vitamin D levels have recently been pub-
lished. In the ﬁrst of these, for 65 994 non-RA subjects,
the relative risk of any cardiovascular event was 1.55 in
those with the lowest vitamin D levels compared with
those with the highest levels,18 whereas in the second,
for 29 640 non-RA subjects, the pooled hazard ratio was
1.54 in the group having low vitamin D levels, compared
with those with the highest levels.84
For a comparison of two independent binomial pro-
portions using Pearson′s χ2 statistic with a two-sided sig-
niﬁcance level of 0.05, a total sample size of 160 patients
assuming an ‘allocation ratio’ of 4 to 6, according to the
prevalence of low versus normal vitamin D levels in the
CARMA study,9 will correspond to a statistical power of
90% (0.902), if the expected proportions having a car-
diovascular event are 50% (in the group having low
Dtotal) and 25% (in the group having normal Dtotal),
respectively. We are not aware of any other studies of
associations between risk of cardiovascular death and
low vitamin D levels in patients with RA, and therefore
the main limitation of the power calculation is the
assumptions on which it is based. One might be con-
cerned, that despite preliminary data supporting this
high hazard, the event rate might be lower, and we are
Table 2 Potential power scenarios, depending on the
proportion of events in the two vitamin D groups, when
taking potentially varying proportions of hypovitaminosis D
in the cohort into account
Potential
percentage
with any
cardiovascular
event in the
group having
vitamin D <
50 nmol/L (%)
Potential
percentage
with any
cardiovascular
event in the
group having
vitamin D ≥
50 nmol/L (%)
Potential
weighting
Patients
with
vitamin
Dtotal <
50 nmol/L:
Patients
with
vitamin
Dtotal ≥
50 nmol/L Power
50 25 1:1 0.912
50 25 2:3 0.902
50 25 3:7 0.865
45 25 1:1 0.760
45 25 2:3 0.749
45 25 3:7 0.701
40 25 1:1 0.526
40 25 2:3 0.520
40 25 3:7 0.480
Table 1 Distribution of baseline variables according to
the Dtotal groups
Baseline variable
Dtotal <
50 nmol/L
Dtotal ≥
50 nmol/L
Age (years), mean
Gender; female, n (%)
Disease duration before
diagnosis (months), mean
Ciclosporin treatment, n (%)
Smoking status (ever), n (%)
Blood pressure (mm Hg),
mean
BMI (kg/m2), mean
CRP (mg/L), mean
IgM RF positive, n (%)
ACPA positive, n (%)
NSJ, mean
NTJ, mean
Known CVD at baseline,
n (%)
NSAID use (ever), n (%)
Antihypertensive treatment
after inclusion, n (%)
Statin treatment after
inclusion, n (%)
Time lost to follow-up
(person-years)
ACPA, anticitrullinated peptide antibodies; BMI, body mass index;
CRP, C reactive protein; CVD, cardiovascular disease; IgM RF,
IgM-rheumatoid factor; NSAID, non-steroidal anti-inflammatory
drug; NSJ, number of swollen joints; NTJ, number of tender joints.
6 Herly M, et al. BMJ Open 2017;7:e014816. doi:10.1136/bmjopen-2016-014816
Open Access
group.bmj.com on July 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
well aware that a lower hazard will lead to an equivalent
lower power. To accommodate these power and sample
size considerations, a table showing different power scen-
arios is presented (table 2).
Prespecification of the analysis
The primary outcome is the occurrence of a ﬁrst cardio-
vascular event, including death from any cardiovascular
cause; this will subsequently be interpreted as an even-
tual harm or beneﬁt from low baseline Dtotal, compared
with the group having normal levels of Dtotal at baseline.
For what we refer to as the crude model, a χ2 test will
be used to evaluate the cardiovascular risk in the two
groups. Comparisons will be presented as risk ratios, and
interpreted based on the absolute risk using risk differ-
ences. Results will be presented with 95% CIs.
The primary statistical models will be based on logistic
regression analysis, with the model including the vitamin
D group, original trial group allocation (CsA or placebo),
and Trial Centre as ﬁxed effects. The primary outcome
will further be analysed using survival analysis, with event
curves based on Kaplan–Meier analysis of the time to ﬁrst
event. The hazard ratio for the primary end point will be
calculated using the Cox regression model. Differences
between numbers of cardiovascular events in the two
Dtotal groups will be analysed using the log-rank test.
Following simple logistic regression analysis, some of
the variables collected at baseline will probably be statis-
tically signiﬁcantly associated with the CVD events. Thus
we will use a multivariable logistic regression, enabling
two or more independent variables in the model—that
is, simultaneously adjusting for more than one factor
that has an impact on the outcome. The relationship
between the outcome and the potential confounding
variables gender, age, smoking status, BMI ≥ 30, ACPA
positivity at baseline, antihypertensive treatment initiated
after inclusion and statin treatment initiated after inclu-
sion will be explored in further sensitivity analyses, using
multivariable logistic regression modelling. Those vari-
ables were chosen because of their well-known associ-
ation with CVD.
Missing outcome data
The adjudication strategy using data from patient jour-
nals might introduce some inconsistencies in the ﬁnal
diagnosis, and thereby misclassiﬁcation of the primary
outcome. Though, we will aim to counteract this, by con-
sulting the third member of the adjudication group in
any cases of disagreement.
Missing values represent a potential source of bias,
and therefore every effort will be undertaken to ensure
sufﬁcient follow-up. There are no missing Dtotal levels at
baseline (Herly M, 2010, abstract only), but we expect
that the collection of journal data for cardiovascular
events or hospitalisation might be insufﬁcient, mainly
because participants may move to another region in
Denmark. There might be sociodemographic differ-
ences in patients moving from one region to another,
but we do not expect changes in these characteristics to
be so different that they will markedly change the esti-
mates. Moreover, Denmark is a small country, with a
relatively homogeneous population, and equal access to
all types of health services, further minimising the risk
of regional differences in prevention and registration of
health outcomes. We will collect follow-up data concern-
ing hospitalisation in all patients moving to one of the
other regions where we have access to patient records, to
minimise the amount of data missing.
If outcome data are missing, we assume that they will
be missing at random, and therefore, data missing
before the patient has had an event, will not bias the
estimates toward a stronger association, but solely under-
estimate the event rate, and thereby the risk of cardiovas-
cular hospitalisation in the cohort. If data are missing
after the ﬁrst cardiovascular event, the primary outcome;
ﬁrst cardiovascular event, will be evaluated as speciﬁed
in the primary analyses.
Data concerning events after patients are lost to
follow-up can also be handled as ‘last observation
carried forward’. For a patient moving to another
region, the last observation will be that the patient is
alive when lost to follow-up. This will possibly lead to an
overestimation of the survival in the cohort, and an
underestimation of the risk of hospitalisation, and ultim-
ately, number of deaths, thereby diminishing the size of
the ﬁnal estimate towards ‘no association’.
To further evaluate the extent of missing data, and
especially the assumption of data missing at random, we
will quantify the number of patient-years in the two
vitamin D groups.
When data are incomplete at the end point, we will
perform sensitivity analyses based on an imputation of
missing values, using two different approaches:
1. Imputation of ‘best’ versus ‘worst’ case scenarios by
replacing missing values with ‘good’ outcomes
(event=no) and ‘poor’ outcomes (event=yes).85
2. Multiple imputations with age, disease duration,
gender, BMI and smoking at baseline entered as
exposure variables.
Where complete cases and different imputation tech-
niques give varying results, we will attempt to understand
this, and report it with appropriate moderation of the
conclusion made in the publication. Because of the risk
of underestimating the event rate when using the last
observation carried forward method, we will put key
emphasis on the results of the best-versus-worst-case
imputation.
Subgroups, interactions and covariates
Stratiﬁed analyses will be performed for the patients
with baseline Dtotal <25 nmol/L. Statistical signiﬁcance
will be deﬁned based on a two-sided signiﬁcance level of
0.05. Thus all results will be expressed as estimates of
the group differences, with 95% CIs to represent preci-
sion of the estimates. p Values will be reported to three
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decimals, whereas p values less than 0.001 will be
reported as < 0.001.
STATA IC1486 will be used for statistical analysis.
Using propensity score analyses to assess the robustness
of the conclusions
An important strength of observational studies like this
is the ability to estimate the inﬂuence of vitamin D at
baseline on cardiovascular events during long-time
follow-up in these patients. This is a crucial strength, as
we would be unable to use a better experimental design
owing to ethical constraints (ie, it is not possible to ran-
domise to low vitamin D). Keeping this in mind, one
drawback of observational studies is that they lack the
ability to randomise their participants into treatment
groups— that is, there is a chance that we infer from
selection bias and confounding by indication. One way
to adjust for this is through the use of a propensity score
analysis. For this analysis, an adjustment will be per-
formed through various forms of propensity scoring
(including stratiﬁcation, matching and regression adjust-
ment). Each form is separately conducted, reviewed and
assessed for its effectiveness in improving the model.
Potential limitations
Instead of being part of the pathogenesis in several dis-
eases, vitamin D might merely be a marker of poor life-
style,87 88 eventually due to RA, or it may be an
independent risk factor of CVD, thereby confounding
our results.
The primary exposure; baseline Dtotal is not rando-
mised; the two vitamin D groups are simply allocated at
baseline, according to the individual Dtotal level at base-
line. The use of vitamin D as a dichotomous variable is
based on international cut-off values,69 to ease the clin-
ical interpretation, though we are aware that we might
lose more subtle differences when not assessing Dtotal as
a continuous variable.
We will report and discuss eventual differences in the
distribution of baseline variables between the two
vitamin D groups, and attempt to evaluate to what
extent, and in what direction this might affect the ﬁnal
estimates.
All patients in the cohort are treated with vitamin D
and calcium supplementation from baseline, in accord-
ance with the National Danish prevention strategy for
osteoporosis in patients with RA. Therefore, a patient
initially evaluated as having low vitamin D levels at base-
line, will presumably achieve normal levels during the
follow-up. If causality between low vitamin D levels and
development of CVD exists, such patients might be ‘mis-
classiﬁed’, thereby leading an eventual association
towards null. Though, we still ﬁnd it relevant to evaluate
if baseline vitamin D levels can predict long-term cardio-
vascular outcomes, despite ‘blurring’ the results by
substitution. We recommend all rheumatologists to
substitute their patients with RA with vitamin D and
calcium, both because it is known that low vitamin D
levels are common in these patients, and as prophylactic
treatment for osteoporosis. However, we also acknow-
ledge that the substitution strategy in our cohort might
diminish the comparability with studies not using
vitamin D and calcium substitution.
A profound association between Dtotal level and other
cardiovascular risk factors may confound the association
between baseline Dtotal and cardiovascular mortality. To
date, associations between vitamin D levels and several
cardiovascular risk factors are well established, as men-
tioned in the introduction, and many of those risk
factors are also associated with low vitamin D levels.
In general, it seems that associations between vitamin
D, RA and CVD are part of an extremely delicate inter-
play, challenging clariﬁcation of causality, and increasing
the risk of confounding.
Despite our attempts to handle these confounders,
the study lacks baseline data, such as markers of early
atherosclerosis, body composition, insulin resistance and
sedentary lifestyle, leading to potential residual con-
founding. Most of this major limitation is due to the
study design, with use of secondary analyses from a prior
randomised controlled trial, with no inﬂuence on the
variables collected at the time of inclusion. Those limita-
tions are regrettable, but we attempt to deal with them
in the discussion section of the ﬁnal paper. We accept
those limitations, because the use of a cohort established
at the millennium has the advantages of long-term
follow-up, and therefore probably an ‘acceptable’
amount of cardiovascular events during this follow-up.
Moreover, despite potential confounders, we still ﬁnd
that the study design is appropriate for evaluating if low
vitamin D levels at baseline can predict long-term CVD
in a cohort of patients with RA treated-to-target and
receiving relevant anti-osteoporotic treatment according
to National Guidelines.
Using a previously designed cohort provides the advan-
tage of long-term follow-up, but also has some major lim-
itations due to the study design—for example, the
exclusion criteria; diastolic blood pressure > 90 mmHg
excludes some patients with a great risk of cardiovascular
disease, and may therefore bias the results towards fewer
incident cardiovascular events. Neither is there informa-
tion about lipid status, and therefore we cannot adjust for
this well-known confounder. An association between
vitamin D and LDL and triglyceride46 89–91 is likely, as
vitamin D is a marker of generally poor lifestyle. This may
lead to an overestimation of the association between low
baseline vitamin D levels and CVD.
Although this cohort was established at the millen-
nium, the aggressive treatment, with both arms receiving
increasing doses of MTX and intra-articular steroid
injections for swollen joints in a step-up treat-to-target
strategy, this strategy is still the ‘gold standard’ for treat-
ment of RA in Denmark. Additionally, although the eli-
gibility criteria led to selection of patients with RA with
few comorbidities at baseline, the long-term follow-up
leads to generalisability of the results.
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Like the present cohort, many other RA cohorts are
strictly selected to avoid comorbidity, and long-term
follow-up studies in RA cohorts with several comorbid-
ities are needed. We try to deal with this issue in the
nearby future by using a Danish inception cohort with
no exclusion criteria, to extensively evaluate cardiovascu-
lar comorbidity during follow-up.92
Deﬁning an event as a hospitalisation, does not take
outpatient contacts into account, thereby potentially
under-rating the incidence of cardiovascular comorbid-
ity. We assume that outpatient contacts are due to minor
comorbidities, and if a more severe comorbidity evolves,
a hospitalisation will ultimately occur, thereby showing
the patient as having an event in the medical records.
The method of adjudicating events using patient′s
medical records is evaluated and validated by Gaede.70–72
We assume this method classiﬁes the events very precisely,
also when compared with other methods, such as using
the Danish National Patient Registry (Lands Patient
Register), which has recently been shown to have general
high validity.93 94 The two methods of classiﬁcation in
patients with RA could be compared, which would indi-
cate the accuracy of the register-based outcome evalu-
ation for CVD in patients with RA.
This study will be a cohort study, and causality under-
lying an eventual association on the effect of vitamin D in
CVD in patients with RA needs to be evaluated in future
studies, preferably in randomised controlled trials, meas-
uring the effect on cardiovascular outcomes of varying
sufﬁciently high doses of vitamin D supplements.
ETHICS AND DISSEMINATION
All patients received verbal and written information before
enrolment, and gave written consent at baseline.62 The
supplemental protocol, which reported cardiovascular
events from the medical records in all 160 patients from
the original CIMESTRA protocol, NCT00209859 (regis-
tered 16 September 2005), is approved by the Danish
Health Authority and the Danish Medicines Agency
(3–3013–930/1/ 10-year patient-record adjudication,
approved 24 April 2015, extension of follow-up to 10
October 2016, approved 10 October 2016) as well as the
Danish Data Protection Agency (2008–58–0035, approved
23 April 2015). Principal investigators in the original study
were Kim Hørslev-Petersen, Merete Lund Hetland and
Kristian-Stengaard Pedersen. This study is registered at
http://www.clinicaltrials.gov as NCT02932644, 12 October
2016.
To disseminate understanding of factors that can
predict cardiovascular outcome in RA, we will attempt to
have a ﬁrst draft ready no later than 1 year after the
adjudication process has ﬁnished. There are gaps in
knowledge concerning prediction of CVD in RA, and
despite great scientiﬁc activity in the ﬁeld of vitamin D
and RA, there are also disparities in this area. If our
hypothesis that low vitamin D levels can predict cardio-
vascular events in RA, no matter if vitamin D is part of
the causality, or just a marker of ‘poor lifestyle’, it is rele-
vant to take this into account in a prediction model, to
be considered by patients, physicians and health politi-
cians. Moreover, it will be important to further investi-
gate if vitamin D supplementation can alter the risk of
cardiovascular events.
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